Related Experiment Video

Updated: Mar 7, 2026

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

7.5K

Management of Antiviral Resistance in Chronic Hepatitis B

Young-Suk Lim1

  • 1Department of Gastroenterology, Liver Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.

Gut and Liver
|February 11, 2017
PubMed

Insights

Tenofofovir disoproxil fumarate (TDF) monotherapy is a reasonable choice for treating drug-resistant chronic hepatitis B (CHB). It offers comparable efficacy to combination therapy with similar safety and lower costs.

Area of Science:

  • Hepatology
  • Virology
  • Pharmacology

Background:

  • Chronic hepatitis B (CHB) treatment aims to prevent liver disease progression.
  • Hepatitis B surface antigen (HBsAg) seroclearance is an ideal treatment endpoint but rarely achieved with nucleos(t)ide analogs (NUCs).
  • Long-term NUC treatment is often necessary for CHB patients, with drug resistance posing a significant challenge.

Purpose of the Study:

  • To evaluate tenofofovir disoproxil fumarate (TDF) monotherapy as a treatment option for drug-resistant hepatitis B virus (HBV) infection.
  • To compare the efficacy and safety of TDF monotherapy with combination therapy (TDF + entecavir (ETV)) in CHB patients.
  • To assess the emergence of HBV resistance mutations during TDF monotherapy.

Main Methods:

  • Review of recent randomized controlled trials (RCTs) comparing TDF monotherapy with TDF + ETV combination therapy.
  • Analysis of antiviral efficacy, emergence of HBV resistance mutations, safety, and cost-effectiveness.
  • Focus on drug-resistant CHB patient populations.

Main Results:

  • TDF monotherapy demonstrated comparable antiviral efficacy to the combination of TDF and ETV.
  • No additional HBV resistance mutations were observed during TDF monotherapy up to 96 weeks.
  • TDF monotherapy presents a lower cost and potentially better safety profile compared to combination therapy.

Conclusions:

  • TDF monotherapy is a viable and reasonable treatment option for drug-resistant CHB.
  • Its comparable efficacy, low resistance risk, reduced cost, and improved safety make it a favorable choice.
  • Further long-term tolerance data may be beneficial for combination therapies.

Keywords:
AdefovirEntecavirLamivudineMonotherapyTenofovir

More Related Videos

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle09:35

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle

Published on: February 1, 2017

14.1K
A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

2.7K

Related Concept Videos

Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
50.1K
Viruses with RNA Genomes01:29

Viruses with RNA Genomes

RNA viruses are categorized into positive-strand, negative-strand, or double-stranded groups based on their genomic structure and replication mechanisms. This classification dictates how they exploit host cellular machinery for protein synthesis and replication. Some RNA viruses also utilize reverse transcription as part of their life cycle, further diversifying their replication strategies.Positive-Strand RNA VirusesPositive-strand RNA viruses have genomes that function directly as messenger...
1.2K
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
304
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Viral Mutations00:36

Viral Mutations

A mutation is a change in the sequence of bases of DNA or RNA in a genome. Some mutations occur during replication of the genome due to errors made by the polymerase enzymes that replicate DNA or RNA. Unlike DNA polymerase, RNA polymerase is prone to errors because it is not capable of “proofreading” its work. Viruses with RNA-based genomes, like HIV, therefore accrue mutations faster than viruses with DNA-based genomes. Because mutation and recombination provide the raw material...
40.3K
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
245